Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.76 per share, up from $2.42 per share in the year-ago period. Johnson & Johnson projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier, according to data from Benzinga Pro.
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kg.
Shares of Johnson & Johnson rose 0.7% to close at $191.08 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- Goldman Sachs analyst Asad Haider maintained a Buy rating and raised the price target from $186 to $212 on Oct. 9, 2025. This analyst has an accuracy rate of 66%.
- Citigroup analyst Joanne Wuensch maintained a Buy rating and boosted the price target from $200 to $213 on Oct. 7, 2025. This analyst has an accuracy rate of 72%.
- B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $175 to $198 on Oct. 3, 2025. This analyst has an accuracy rate of 72%.
- Guggenheim analyst Vamil Divan upgraded the stock from Neutral to Buy and raised the price target of $167 to $206 on Sept. 23, 2025. This analyst has an accuracy rate of 78%.
- JP Morgan analyst Michael Weinstein maintained a Neutral rating and raised the price target from $185 to $200 on Sept. 16, 2025. This analyst has an accuracy rate of 72%
Considering buying JNJ stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
